Optimizing Therapy Sequencing in CLL

A recent study has found that higher serum levels of B-cell activating factor and anti-CCP3 are associated with a reduced risk of developing chronic lymphocytic leukemia (CLL), suggesting potential biomarkers for assessing CLL risk.

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.

A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.

A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic leukemia (CLL).

A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.

As the treatment landscape for chronic lymphocytic leukemia (CLL) has moved into an era where targeted treatments are a mainstay of treatment, new opportunities to tailor therapy have emerged.